Looks like you’re on the UK site. Choose another location to see content specific to your location
Takeda and Noile-Immune Biotech to develop new cancer therapies
Takeda has announced a new cancer drug research collaboration with the Japanese biotechnology company Noile-Immune Biotech.
The alliance aims to develop next-generation chimeric antigen receptor T (CAR-T) cell therapies, based on research from Professor Koji Tamada at Yamaguchi University, to which Noile-Immune has an exclusive licence.
CAR-T therapies produce cytokines, chemokines and other molecules that can influence or alter tumour microenvironments to enhance the effect of the therapy. The companies intend to use this technology to treat a broad range of cancers.
In addition to providing resources required for implementation of the alliance, Takeda will make a technology access payment to Noile-Immune Biotech, as well as an equity investment.
Takeda will receive an exclusive option to obtain licensing rights for the development and commercialisation of Noile-Immune's pipeline and products resulting from this partnership.
Chris Arendt, head of the oncology drug discovery unit for Takeda, said: "This collaboration is another example of our commitment to invest in highly innovative technologies and to work with top external scientific and clinical teams as we seek to deliver therapies that address the needs of patients with cancer."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard